You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Details for Patent: 10,543,274

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,543,274 protect, and when does it expire?

Patent 10,543,274 protects PEPAXTO and is included in one NDA.

This patent has sixty-four patent family members in twenty-eight countries.

Summary for Patent: 10,543,274

Title:	Lyophilized preparation of cytotoxic dipeptides
Abstract:	The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; .beta.-cyclodextrin; ocyclodextrin; hydroxypropyl-.beta.-cyclodextrin; sulfobutylether-.beta.-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.
Inventor(s):	Spira; Jack (Tyreso, SE), Lehmann; Fredrik (Knivsta, SE)
Assignee:	ONCOPEPTIDES AB (Stockholm, SE)
Application Number:	16/382,276
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 10,543,274

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Oncopeptides Ab	PEPAXTO	melphalan flufenamide hydrochloride	POWDER;INTRAVENOUS	214383-001	Feb 26, 2021		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFACTORY TO AT LEAST 1 PROTEASOME INHIBITOR, 1 IMMUNOMODULATORY AGENT, AND 1 ANTI-CD38 MAB) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR LINES OF THERAPY	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,543,274

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	1150371	Apr 28, 2011

International Family Members for US Patent 10,543,274

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012247545	⤷ Try a Trial
Brazil	112013027584	⤷ Try a Trial
Canada	2833500	⤷ Try a Trial
Canada	3024230	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.